AUROBINDO PHARMA |
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
| 1.154 INR | +0,15 % |
|
+7,18 % | +6,41 % |
Resumen de negocios
- medicamentos genéricos: para el tratamiento de enfermedades neurológicas, cardiovasculares, víricas, gastroenterológicas, oftalmológicas y crónicas;
- ingredientes farmacéuticos activos.
A finales de marzo de 2018, el grupo explotaba 23 centros de producción en India (19), Estados Unidos (3) y Brasil.
Las ventas netas se distribuyen geográficamente de la siguiente manera: India (12%), Estados Unidos (46,5%), Europa (31,2%) y otros (10,3%).
Número de empleados: 23 451
Ventas por actividad
| INR en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
Generic Pharmaceuticals and Related Services
97,0
%
| 231 243 | 98,6 % | 241 044 | 97,0 % | +4,24 % |
Services
2,1
%
| 2 422 | 1,0 % | 5 128 | 2,1 % | +111,67 % |
Government Incentive Schemes
0,9
%
| 314 | 0,1 % | 2 176 | 0,9 % | +593,81 % |
Scrap
0,1
%
| 197 | 0,1 % | 207 | 0,1 % | +5,03 % |
Ventas por región
| INR en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
United States
45,2
%
| 105 208 | 44,9 % | 112 421 | 45,2 % | +6,86 % |
Europe
29,1
%
| 78 813 | 33,6 % | 72 430 | 29,1 % | -8,10 % |
Rest of the World
14,6
%
| 23 835 | 10,2 % | 36 222 | 14,6 % | +51,97 % |
India
11,1
%
| 26 700 | 11,4 % | 27 482 | 11,1 % | +2,93 % |
Directores
| Directores | Puesto | Edad | Desde |
|---|---|---|---|
| Founder | 66 | 26/12/86 | |
| Director of Finance/CFO | - | 01/01/13 | |
B. Adi Reddy
CMP | Compliance Officer | - | 01/06/16 |
| Director/Board Member | - | 01/01/16 | |
| Corporate Officer/Principal | 68 | 01/02/00 | |
| Corporate Officer/Principal | 59 | 01/02/16 |
Administradores
| Administradores | Puesto | Edad | Desde |
|---|---|---|---|
| Founder | 66 | 26/12/86 | |
| Founder | 66 | 26/12/86 | |
| Director/Board Member | 64 | 27/05/03 | |
| Director/Board Member | 39 | 27/09/07 | |
| Director/Board Member | 67 | 09/02/23 | |
| Director/Board Member | 64 | 10/02 | |
Savita Mahajan
BRD | Director/Board Member | 65 | 16/12/17 |
| Director/Board Member | 52 | 05/11/20 | |
| Director/Board Member | - | 01/01/16 |
Clase de acciones
| Vote | Quantity | Flotante | Autocontrol | Total Float | |
|---|---|---|---|---|---|
| Acción A | 1 | 585 938 609 | 280 869 458 ( 47,93 %) | 0 | 47,93 % |
Información de la empresa
Aurobindo Pharma Ltd.
Plot No. 1, Hyderabad Knowledge City Raidurg Panmaktha, Galaxy
500032, Hyderabad
+91 40 6672 5000
http://www.aurobindo.com
Empresas del grupo
| Nombre | Categoría y sector |
|---|---|
Auronext Pharma Pvt Ltd.
 Auronext Pharma Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Aurobindo Pharma Ltd., Auronext Pharma Pvt Ltd. is a pharmaceutical company founded in 2009. The private company is based in Hyderabad, India. The Indian company manufactures and supplies pharmaceutical products. |
Pharmaceuticals: Major
|
APL Healthcare Ltd.
 APL Healthcare Ltd. Pharmaceuticals: MajorHealth Technology Part of Aurobindo Pharma Ltd., APL Healthcare Ltd. is a fully integrated pharmaceutical company based in Hyderabad, IN. The private company also has a strong focus on sustainability and social responsibility, with initiatives in place to ensure compliance with social accountability standards, human rights policies, and progressive health and safety practices. APL Healthcare is dedicated to providing access to healthcare and has programs in place to support this goal. The Indian company offers a range of products and services including formulations, custom synthesis, peptides, and R & D. APL Healthcare is committed to quality and safety, with manufacturing facilities approved by various regulatory bodies including the US FDA, UK MHRA, TGA, MCC-SA, EMA, and ANVISA. |
Pharmaceuticals: Major
|
Silicon Life Sciences Pvt Ltd.
 Silicon Life Sciences Pvt Ltd. Medical SpecialtiesHealth Technology Part of Aurobindo Pharma Ltd., Silicon Life Sciences Pvt Ltd. is an Indian company that manufactures non sterile penems. The private company is based in Parawada, India. The company was founded in 2008. Silicon Life Sciences was acquired by Aurobindo Pharma Ltd. on August 10, 2013 for $1.07 million. |
Medical Specialties
|
Eugia Pharma Specialities Ltd.
 Eugia Pharma Specialities Ltd. Miscellaneous Commercial ServicesCommercial Services Eugia Pharma Specialities Ltd. develops, manufactures and markets hormonal and oncology generic formulations. The company is headquartered in Hyderabad, India. |
Miscellaneous Commercial Services
|
Auro Peptides Ltd.
 Auro Peptides Ltd. Chemicals: SpecialtyProcess Industries Part of Aurobindo Pharma Ltd., Auro Peptides Ltd. is an Indian company that manufactures peptides. The private company is based in Hyderabad, India. |
Chemicals: Specialty
|
Apitoria Pharma Pvt Ltd.
| |
Curateq Biologics Pvt Ltd.
| |
Aurobindo Pharma Foundation
|
Investment Trusts/Mutual Funds
|
Lyfius Pharma Pvt Ltd.
|
Ventas por actividad
Ventas por región
Revisiones del BPA
| Varia. 1 de ene. | Capi. | |
|---|---|---|
| +6,41 % | 8087,37 M | |
| +34,00 % | 664 mil M | |
| +29,29 % | 567 mil M | |
| -7,75 % | 354 mil M | |
| +18,53 % | 330 mil M | |
| +4,95 % | 286 mil M | |
| +13,79 % | 234 mil M | |
| +4,93 % | 199 mil M | |
| -9,78 % | 196 mil M | |
| -4,89 % | 148 mil M |
- Bolsa de valores
- Acciones
- Acción AUROPHARMA
- Empresa Aurobindo Pharma
